Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(80.0%)

Phase 2

1(20.0%)

5Total

Phase 1(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06748872Phase 1Not Yet Recruiting

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

Role: lead

NCT03503968Phase 1Terminated

TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms

Role: lead

NCT04464889Phase 1Withdrawn

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Role: lead

NCT02405338Phase 1Completed

DC Vaccination for Post-remission Therapy in AML

Role: lead

NCT02029352Phase 2Completed

Topical Green Tea Ointment in Treatment of Superficial Skin Cancer

Role: collaborator

All 5 trials loaded